Navigation Links
Accelr8 to Hold 2012 Annual Meeting of Shareholders; Product Development Continues with Launch Expected in 2015
Date:12/11/2012

DENVER, Dec. 11, 2012 /PRNewswire/ -- Accelr8 Technology Corporation (NYSE MKT: AXK) will hold its 2012 Annual Meeting of Shareholders (the "Annual Meeting") at 2:30 p.m., local time, on Wednesday, December 12, 2012, at the Warwick Hotel Denver, 1776 Grant Street, Denver, Colorado 80203.

Progress towards the company's IVD product launch continues, with management expecting to be in development through 2014, launching in 2015, with additional clinical trials continuing through 2016.

About Accelr8

Accelr8 Technology Corporation (www.accelr8.com) is focused on developing and commercializing innovative instrumentation for the rapid identification and antibiotic susceptibility testing of infectious pathogens.  The Company's BACcel™ platform utilizes a proprietary culture-free process with both genomic and phenotypic detection technologies that decrease time to result while maintaining high sensitivity and specificity. 

Disclaimer Regarding Forward-Looking Statements

Certain statements in this news release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended.  Statements regarding future prospects and developments are based upon current expectations and involve certain risks and uncertainties that could cause actual results and developments to differ materially from the forward-looking statement, including those detailed in the Company's filings with the SEC.  The Company does not undertake an obligation to publicly update or revise any forward-looking statements, whether as a result of new information or future events.


'/>"/>
SOURCE Accelr8 Technology Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1

Related medicine technology :

1. Accelr8 Appoints Steve Reichling Chief Financial Officer
2. MiMedx Group to Present at the 6th Annual OneMedForum
3. Follow-up Results of Phase 2 Study of Investigational Agent, Ibrutinib, in Relapsed/Refractory Mantle Cell Lymphoma Presented at American Society of Hematology Annual Meeting
4. Ambit and Astellas Announce Presentation of Results from Phase 2 ACE Study of Quizartinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia (AML) at the 54th Annual Meeting of the American Society of Hematology
5. Hospira to Present at the J.P. Morgan 31st Annual Healthcare Conference Jan. 8, 2013
6. Thoratec Presentation At Oppenheimer 23rd Annual Healthcare Conference To Be Webcast
7. Henry Schein To Present At The Oppenheimer 23rd Annual Healthcare Conference
8. PROLOR Biotech To Present Preclinical Data On Its Long-Acting Clotting Factor Vlla At 2012 ASH Annual Meeting
9. Accuray Incorporated to Speak at 23rd Annual Oppenheimer Healthcare Conference
10. HeartWare Presentation at the Oppenheimer 23rd Annual Healthcare Conference to be Webcast
11. Arena Pharmaceuticals to Present at the Oppenheimer 23rd Annual Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/4/2015)... , Aug. 4, 2015  Rigel Pharmaceuticals, Inc. (Nasdaq: ... quarter and six months ended June 30, 2015. ... ITP are progressing and we continue to expect results ... , president and chief executive officer of Rigel. "We ... clinical programs, including evaluating fostamatinib for new treatment indications, ...
(Date:8/4/2015)... 2015  Dr. Keesha Ewers of ... approval of flibanserin, or what is being touted ... of decreased female sexual desire back several decades. ... and addressing libido as a singular symptom with ... Photo - ...
(Date:8/4/2015)...  MEI Pharma, Inc. (Nasdaq: MEIP ), an oncology ... cancer, announced today that Daniel P. Gold , Ph.D., ... Wedbush PacGrow Healthcare Conference on Tuesday, August 11, 2015 at ... in New York . A live webcast ... A replay will be available approximately one hour after the ...
Breaking Medicine Technology:Rigel Announces Second Quarter 2015 Financial Results 2Rigel Announces Second Quarter 2015 Financial Results 3Rigel Announces Second Quarter 2015 Financial Results 4Rigel Announces Second Quarter 2015 Financial Results 5Rigel Announces Second Quarter 2015 Financial Results 6Potential FDA Approval of "Pink Viagra" Sends Wrong Message 2Potential FDA Approval of "Pink Viagra" Sends Wrong Message 3Potential FDA Approval of "Pink Viagra" Sends Wrong Message 4Potential FDA Approval of "Pink Viagra" Sends Wrong Message 5MEI Pharma to Present at Wedbush PacGrow Healthcare Conference 2
... FORT MYERS, Fla., May 11, 2011 Radiation ... radiation therapy centers, today announced financial results for the first ... the first quarter of 2011 were $156.5 million, an increase ... same quarter of 2010. The increase in revenue was principally ...
... 2011 Doctors in Germany are among the first ... with the REVIVE™ SE, a new self-expanding blood clot ... and restore blood flow to the brain in patients ... Inc., a global neuroscience and neurovascular company, received Conformite ...
Cached Medicine Technology:Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 2Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 3Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 4Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 5Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 6Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 7Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 8Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 9Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 10Radiation Therapy Services Holdings, Inc. Reports First Quarter 2011 Financial Results 11Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 2Doctors in Germany Among First to Use New Self-Expanding Clot Removal Device for Ischemic Stroke 3
(Date:8/4/2015)... ... August 04, 2015 , ... Worldwide Power ... Products is expanding its reach in Texas. Effective July 1st of this year, ... Texas generator division. With the North Texas acquisition, Worldwide Power Products (“WPP”) ...
(Date:8/4/2015)... ... 04, 2015 , ... Recent studies in the ... in binge drinking among certain populations and specific locations. Researchers, who ... examine trends and evidence to help facilitate health care treatment to meet current ...
(Date:8/4/2015)... NJ (PRWEB) , ... August 04, 2015 , ... Members ... on quality care metrics – at a cost that is nine percent lower -- ... Blue Cross Blue Shield of New Jersey’s patient-centered programs. , “The promise of ...
(Date:8/4/2015)... Ohio (PRWEB) , ... August 04, 2015 , ... ... have up-to-date immunizations, especially those entering kindergarten. All required immunizations are covered for ... rules, which means that children who aren’t caught up with their immunizations may ...
(Date:8/4/2015)... ... August 04, 2015 , ... NutraScience Labs , a ... services, joined over 200 other Long Island-based corporations as participants in the 10th ... at Jones Beach State Park in Wantagh, New York. , According to Mindy ...
Breaking Medicine News(10 mins):Health News:North Texas Acquisition Press Release 2Health News:DARA Responds To International Trends in Binge Drinking 2Health News:DARA Responds To International Trends in Binge Drinking 3Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 2Health News:Horizon BCBSNJ: 2014 Results Show Patient-Centered Care Continues to Deliver on Promise of Better Quality Care at a Lower Cost 3Health News:Buckeye Health Plan Reminds Parents to Keep Immunizations In Mind As School Year Kicks Off 2Health News:NutraScience Labs "Steps Up" to the 2015 Marcum Workplace Challenge 2
... , NEW YORK, Dec. 11 Often called "the ... Miracle,s for their significant contribution to today,s beauty industry ... Award in the mass skin care market category. ... My Goodbye Acne System , the first ...
... The National Medical Association (NMA) applauds the announcement ... Tom Daschle as the Secretary of Health and Human ... of Health and Human Services. , We ... to provide a comprehensive national health care reform benefiting ...
... WASHINGTON, Dec. 11 Speaker Nancy Pelosi released the following ... Leader Tom Daschle as Secretary of Health and Human Services ... Office of Health Reform: , , ... Services and his selection as Director of the new White ...
... Dec. 11 The American Academy of Orthopaedic Surgeons ... guideline on "Treatment of Osteoarthritis of the Knee". These ... less invasive than knee replacement surgery. While a wide ... tailored to individual patients after discussions with their physicians. ...
... Clinic researchers have discovered that a chemical known as ... the effectiveness of tamoxifen in treating breast cancer, and ... way. , Their study, being presented at the Cancer ... 31st annual San Antonio Breast Cancer Symposium, finds that, ...
... MINNEAPOLIS/ST. PAUL (Dec. 11, 2008) The University of Minnesota has received ... Family Foundation. Goals for the funding, to be paid over five ... to accelerate the timeline to translate it into a viable cure for ... The gift is the ...
Cached Medicine News:Health News:DR. MIRACLE'S Wins 2008 WWD Beauty Biz Award: Breakthrough Product of the Year!!! 2Health News:National Medical Association Applauds Choice of Health and Human Services Secretary 2Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 2Health News:AAOS Issues New Clinical Practice Guideline for Osteoarthritis of the Knee 3Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 2Health News:Mayo Clinic researchers find tamoxifen's power comes from endoxifen 3Health News:University of Minnesota receives $40 million for type 1 diabetes research 2Health News:University of Minnesota receives $40 million for type 1 diabetes research 3Health News:University of Minnesota receives $40 million for type 1 diabetes research 4
... Designed To Safely And Easily ... Smaller Incision.,Specially Designed To Cut And ... With Ease With One Instrument.,New Miniaturized ... Phaco Incision For Explantation Of A ...
... 8-12108 : Designed To Be Used ... Length Radials Placed On The Cornea For Making ... Be Used With The Gills Nomograms. 6mm & ... For Making Limbal Relaxing Incisions.5mm Inner Circle Assists ...
... Designed To Rest Either Nasally Or ... Over, Allowing Eyelids To Be Opened ... Widest Possible Aperture., ,Open And Close ... Access To The Globe During Clear ...
... Jaw Design Holds The Lens Securely ... Polished Blades Keep The Optic From ... Control Over Release Of The Optic.,Wide ... Tilting During Insertion.,Reusable, Autoclaveable, Made In ...
Medicine Products: